Home / Resource Library / Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy

Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy

Results of a phase II trial of Idelalisib in treating relapsed/refractory follicular lymphoma